Incyte Corp (BSP:I1NC34)
R$ 221.1 0 (0%) Market Cap: 85.19 Bil Enterprise Value: 75.12 Bil PE Ratio: 541.07 PB Ratio: 4.61 GF Score: 77/100

Incyte Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 12:30PM GMT
Release Date Price: R$211.92
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning, and Happy New Year, everyone. Welcome to the 40th Annual and Second, and hopefully the last time, Virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, I'm the senior large-cap biotech analyst, and it's my pleasure to introduce Herve Hoppenot, the Chairman and CEO of Incyte, our first company to present here today. Please note that following Herve's presentation, we will have a Q&A session right here in the same Zoom room. (Operator Instructions)

And with that, let me turn things over to Herve to get us started. So, Herve, thank you for being here.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Thank you, Cory. It's good to be first and it's a pleasure to speak about Incyte this morning. So I will call the slide numbers as I go through the presentation. So on Slide 2, I must state that safe harbor rules govern my remarks. Any forward-looking statement that I make, can I ask that you please review

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot